Celularity Releases CEO Letter to Shareholders
Rhea-AI Summary
Celularity (Nasdaq: CELU) released a CEO letter outlining a sharper focus on placental-derived cellular therapies for longevity and age-related disease.
The company out-licensed its biomaterials business to NexGel for up to $30 million, eliminated nearly $13 million of recorded liabilities, highlighted growing physician demand for cenplacel-L, emphasized early commercial efforts in Florida with Fountain Life, and announced Rick Gonzalez as Chief Commercial Officer while acknowledging residual debt and capital constraints.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- Out-licensing biomaterials assets to NexGel for consideration of up to $30 million
- Elimination of nearly $13 million of recorded liabilities through strategic structuring
- Refocused strategy on core placental-derived cellular therapies for longevity and age-related disease
- Growing physician demand and early cenplacel-L commercialization efforts in Florida
- Existing manufacturing capacity and inventory positioned to support anticipated cenplacel-L demand
- Appointment of Rick Gonzalez as Chief Commercial Officer to lead commercial strategy
Negative
- Company notes existing residual debt obligations that require disciplined execution
- Ongoing capital constraints and demanding capital markets environment for cellular therapy companies
- Out-licensing of biomaterials business removes a historical source of meaningful revenue
News Market Reaction – CELU
On the day this news was published, CELU declined 2.45%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 29 | Nasdaq 10-Q notice | Negative | +5.9% | Nasdaq notice for late Form 10-Q and potential compliance timeline. |
| May 01 | 10-K filing, compliance | Positive | +2.8% | Filed 2025 Form 10-K, regained Nasdaq compliance and detailed transformation. |
| Apr 21 | NexGel deal closing | Positive | -1.6% | Closed NexGel biomaterials asset sale, received cash and note, reduced debt. |
| Apr 17 | Nasdaq 10-K notice | Negative | +0.8% | Nasdaq notice for late Form 10-K and outlined compliance plan window. |
| Mar 12 | NexGel partnership update | Positive | -0.8% | Reiterated NEXGEL partnership and expected closing for biomaterials franchise. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Across recent news, price moves often diverged from headline tone, with 4 divergences vs 1 alignment, including positive reactions to Nasdaq deficiency notices and mixed responses to strategic transactions.
Over the past few months, Celularity has balanced regulatory compliance issues with strategic refocusing. Nasdaq notices in April and May 2026 flagged late Form 10-K and 10-Q filings, yet shares sometimes rose after these updates. The company closed the NexGel biomaterials transaction on April 21, 2026, receiving cash and a convertible note while retiring nearly $13M of debt to sharpen its longevity and cell therapy focus. Filing the 2025 Form 10-K on May 1, 2026 restored Nasdaq compliance and highlighted this strategic transformation, which today’s CEO letter further elaborates.
Regulatory & Risk Context
Key Terms
allogeneic medical
immunomodulatory medical
natural killer cell medical
senoblative therapy medical
cell therapy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, today announced that it has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Celularity's Founder, Chairman, and Chief Executive Officer, to the Investor Relations section of its website. The letter is also included below.
Dear Fellow Shareholders,
I want to take this opportunity to provide an important update on the developments at Celularity over the past several months particularly in the context of evolving clinical and regulatory progress. At the same time, we recognize that the broader biotechnology sector, and cellular therapy companies in particular, continue to operate in a highly selective and challenging capital markets environment. Celularity’s leadership has taken important steps to sharpen our strategic focus, strengthen our financial position and enable Celularity to pursue the opportunities we believe are most closely aligned with our founding vision. These actions are intended to streamline our business and concentrate resources where we believe we can create durable long-term value.
As previously announced, we completed a transaction with NexGel, Inc. to out-license the commercial assets of our biomaterials business for consideration of up to
Celularity was founded on the belief that the placenta represents a powerful and ethical biological resource with the potential to transform medicine on a global scale. Together with Peter Diamandis, M.D., one of the leading voices in the global longevity and exponential technology movements, I launched Celularity around a shared conviction: that placental-derived cellular therapies could play an anchoring role in extending human health span, addressing age-related disease and improving human performance. That vision continues to guide our strategy today.
Celularity sits at a unique intersection of regenerative medicine, immunology and aging biology. Our technologies are designed to harness the intrinsic biological properties of placental cells to address inflammation and the degenerative changes associated with aging. As global interest in longevity, cellular medicine, and regenerative therapies continues to expand, we believe Celularity is uniquely positioned to be a leader in this exciting area of medical innovation.
Central to our renewed focus is our most mature cell therapy product, cenplacel-L. Cenplacel-L is a placental-derived allogeneic cell therapy in the broader category of stem-cell and regenerative medicine, developed from postpartum placental tissue and designed to deliver the regenerative, immunomodulatory and anti-inflammatory potential of placental cells and reflects more than two decades of research by Celularity and its predecessor company, Celgene Cellular Therapeutics.
We believe cenplacel-L has the potential to play an important role in the emerging global market for stem-cell and regenerative cellular therapies, particularly in jurisdictions where regulatory frameworks permit physician-directed access to such therapies. These markets offer Celularity the opportunity to generate early commercial activity and build real-world clinical experience while continuing to evaluate opportunities to advance cenplacel-L through traditional regulatory pathways.
We are excited that physician interest in cenplacel-L has been strong. We are seeing demand from physicians seeking access to high-quality, responsibly manufactured placental-derived cellular therapies for appropriate patients in permissive markets. This demand includes interest from our affiliate partners at Fountain Life, whose physician network, focused on longevity, performance, and proactive health, has a mission closely aligned with Celularity. We believe the next phase of regenerative medicine will be defined not only by physician demand, but by manufacturing rigor, quality systems, regulatory discipline, and clinically responsible access. We believe these are areas where Celularity is well-positioned to differentiate.
Since emerging as a spin-off from Celgene at the end of 2017, Celularity has distinguished itself from other cellular medicine companies through our ability to generate revenues from placental biomaterials, CDMO and biobanking services, and the sale of cenplacel-L. While still early in the commercialization process, we believe growth in cenplacel-L revenues in 2026 will be driven principally by increasing physician participation and patient adoption in Florida, where the evolving regulatory framework and our collaboration with Fountain Life are helping to create an important initial market for placental-derived cellular therapies. We believe this market can provide a meaningful foundation for early commercial growth while also contributing valuable real-world clinical experience. Importantly, our current manufacturing infrastructure and existing inventory position us well to support anticipated demand, and we believe we have abundant capacity to meet expected growth while maintaining the quality standards and manufacturing discipline central to Celularity’s platform. As we scale, we intend to report on key metrics such as the number of participating centers, repeat physician utilization, and patient cohorts to provide greater transparency into the trajectory of this emerging commercial opportunity.
As Celularity enters this next phase, we are pleased to welcome Rick Gonzalez as Chief Commercial Officer. Rick will be responsible for leading Celularity’s commercial strategy, with a focus on expanding physician access to cenplacel-L and related Celularity products. His leadership will be critical as we seek to translate growing physician interest into a disciplined and scalable commercial model. One that broadens access while maintaining the quality, manufacturing rigor, and scientific integrity central to Celularity’s platform.
Cenplacel-L also remains an important part of Celularity’s longer-term clinical strategy. Previously investigated as PDA-001 and PDA-002, cenplacel-L has been studied across multiple indications, and we continue to evaluate opportunities to return this program to the clinic in the United States in areas where placental-derived cellular therapy may address significant unmet medical need.
We are also continuing to explore the potential of our natural killer cell program, CYNK-001, including its potential application as a senoblative therapy. Senescent cells accumulate with age and contribute to tissue dysfunction, degenerative disease and declining physiological performance. The ability to selectively eliminate these cells represents an emerging approach to addressing biological mechanisms that influence aging and health span. Together, we believe cenplacel-L and CYNK-001 represent complementary pillars of a differentiated, placenta-derived longevity platform designed to address both the consequences and underlying biological drivers of age-related decline.
While we are encouraged by the opportunities ahead, we remain realistic about the challenges facing Celularity. Like many companies advancing novel cellular therapies, we operate in a demanding capital environment. Our existing residual debt obligations and capital constraints require discipline and careful execution. In parallel, we are actively evaluating opportunities to support the business through strategic partnerships, non-dilutive sources of capital, and disciplined geographic expansion in markets where the regulatory environment and physician demand may enable responsible near-term commercialization. The actions we are taking, including the NexGel transaction and our renewed focus on cell therapy in longevity, are intended to strengthen Celularity’s financial position and concentrate our resources on the programs where we believe our science, manufacturing capabilities and strategic relationships can create the greatest long-term value.
Celularity is entering a new phase of focused execution. With a more streamlined operating structure, a differentiated placental-derived cellular therapy platform, growing physician interest in cenplacel-L, and the addition of experienced commercial leadership to expand physician access, we believe Celularity is well-positioned to pursue meaningful near-term commercial opportunities while continuing to advance its broader mission in longevity, regenerative medicine, and cellular therapy to preserve human performance. Thank you for your continued support and confidence in Celularity.
Sincerely,
Robert J. Hariri, M.D., Ph.D.
Founder, Chairman and Chief Executive Officer
Celularity Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and include, without limitation, statements regarding Celularity’s strategy, business plans, objectives, expectations and prospects; its focus on longevity, regenerative medicine, cellular therapy, age-related disease and human performance; the anticipated benefits of the NexGel transaction, including liability reduction, business simplification and the reallocation of resources; the potential clinical, regulatory, commercial and market opportunities for cenplacel-L, including physician demand, patient adoption and revenue growth; Celularity’s collaboration with Fountain Life and the anticipated contributions of its commercial leadership; Celularity’s plans to evaluate opportunities to advance cenplacel-L through traditional regulatory pathways or return the program to the clinic in the United States; the potential application of CYNK-001 as a senoblative therapy; the potential of Celularity’s placenta-derived cellular therapy platform; and Celularity’s ability to support its business through strategic partnerships, non-dilutive capital and other financing or strategic alternatives. These forward-looking statements are based on current expectations, estimates, forecasts, assumptions and beliefs and are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among others, risks related to Celularity’s ability to execute its strategy; manage its debt obligations, liquidity needs and capital constraints; obtain sufficient financing or strategic support on acceptable terms or at all; develop, manufacture, commercialize, market and sell cenplacel-L and its other products and product candidates; navigate applicable regulatory frameworks and changes in laws, regulations, policies or enforcement priorities; obtain, maintain or expand any required regulatory approvals, clearances, authorizations or permissions; conduct or resume clinical development activities; and the other risks and uncertainties described in Celularity’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent filings. Forward-looking statements speak only as of the date they are made. Celularity undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Celularity Investor Contact:
Carlos Ramirez, Senior Vice President
Celularity Inc.
Carlos.ramirez@celularity.com
